Skip to main content
. 2012 Aug 27;2(3):23–33. doi: 10.3390/diagnostics2030023

Figure 2.

Figure 2

(a) Surface plasmon resonance (SPR)-based anti-human fetuin A (HFA) immunoassay using various EDC-based strategies for crosslinking anti-HFA antibodies to APTES-functionalized SPR gold chips; (b) SPR response units corresponding to the binding of capture anti-HFA antibodies by the various strategies. The values are average of four repeats in different flow cells. The errors bars represent standard deviation.